73 related articles for article (PubMed ID: 23274166)
1. PAX3 promotes tumor progression via CD105 signaling.
Fang WH; Ahmed M; Wang Q; Li HM; Kumar P; Kumar S
Microvasc Res; 2013 Mar; 86():42-3. PubMed ID: 23274166
[No Abstract] [Full Text] [Related]
2. Transforming growth factor-β1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion.
Wang Y; Lui WY
Eur J Cancer; 2012 Dec; 48(18):3475-87. PubMed ID: 22647687
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium.
Benetti A; Berenzi A; Gambarotti M; Garrafa E; Gelati M; Dessy E; Portolani N; Piardi T; Giulini SM; Caruso A; Invernici G; Parati EA; Nicosia R; Alessandri G
Cancer Res; 2008 Oct; 68(20):8626-34. PubMed ID: 18922939
[TBL] [Abstract][Full Text] [Related]
4. Differential PAX3 functions in normal skin melanocytes and melanoma cells.
Medic S; Rizos H; Ziman M
Biochem Biophys Res Commun; 2011 Aug; 411(4):832-7. PubMed ID: 21802410
[TBL] [Abstract][Full Text] [Related]
5. Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.
Schönherr M; Bhattacharya A; Kottek T; Szymczak S; Köberle M; Wickenhauser C; Siebolts U; Saalbach A; Koczan D; Magin TM; Simon JC; Kunz M
Pigment Cell Melanoma Res; 2014 May; 27(3):418-30. PubMed ID: 24406113
[TBL] [Abstract][Full Text] [Related]
6. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma.
Pardali E; van der Schaft DW; Wiercinska E; Gorter A; Hogendoorn PC; Griffioen AW; ten Dijke P
Oncogene; 2011 Jan; 30(3):334-45. PubMed ID: 20856203
[TBL] [Abstract][Full Text] [Related]
7. PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways.
Fang WH; Wang Q; Li HM; Ahmed M; Kumar P; Kumar S
J Cell Mol Med; 2014 Jan; 18(1):38-48. PubMed ID: 24188742
[TBL] [Abstract][Full Text] [Related]
8. Endoglin negatively regulates transforming growth factor beta1-induced profibrotic responses in intestinal fibroblasts.
Burke JP; Watson RW; Mulsow JJ; Docherty NG; Coffey JC; O'Connell PR
Br J Surg; 2010 Jun; 97(6):892-901. PubMed ID: 20473999
[TBL] [Abstract][Full Text] [Related]
9. P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness.
Thuault S; Hayashi S; Lagirand-Cantaloube J; Plutoni C; Comunale F; Delattre O; Relaix F; Gauthier-Rouvière C
Oncogene; 2013 Apr; 32(15):1876-87. PubMed ID: 22710718
[TBL] [Abstract][Full Text] [Related]
10. PAX3 and SOX10 activate MET receptor expression in melanoma.
Mascarenhas JB; Littlejohn EL; Wolsky RJ; Young KP; Nelson M; Salgia R; Lang D
Pigment Cell Melanoma Res; 2010 Apr; 23(2):225-37. PubMed ID: 20067553
[TBL] [Abstract][Full Text] [Related]
11. PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression.
He S; Li CG; Slobbe L; Glover A; Marshall E; Baguley BC; Eccles MR
Melanoma Res; 2011 Feb; 21(1):24-34. PubMed ID: 21164369
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of alternative isoforms of the transcription factor PAX3 in melanocytes in vitro.
Wang Q; Kumar S; Slevin M; Kumar P
Cancer Res; 2006 Sep; 66(17):8574-80. PubMed ID: 16951170
[TBL] [Abstract][Full Text] [Related]
13. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.
Kato S; Kubota K; Shimamura T; Shinohara Y; Kobayashi N; Watanabe S; Yoneda M; Inamori M; Nakamura F; Ishiguro H; Nakaigawa N; Nagashima Y; Taguri M; Kubota Y; Goshima Y; Morita S; Endo I; Maeda S; Nakajima A; Nakagama H
Cancer Sci; 2011 Nov; 102(11):2029-37. PubMed ID: 21812859
[TBL] [Abstract][Full Text] [Related]
14. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
Kubic JD; Lui JW; Little EC; Ludvik AE; Konda S; Salgia R; Aplin AE; Lang D
J Biol Chem; 2015 Sep; 290(36):21901-14. PubMed ID: 26205821
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes.
Tatzel J; Poser I; Schroeder J; Bosserhoff AK
Pigment Cell Res; 2005 Apr; 18(2):92-101. PubMed ID: 15760338
[TBL] [Abstract][Full Text] [Related]
16. PAX3 is expressed in human melanomas and contributes to tumor cell survival.
Scholl FA; Kamarashev J; Murmann OV; Geertsen R; Dummer R; Schäfer BW
Cancer Res; 2001 Feb; 61(3):823-6. PubMed ID: 11221862
[TBL] [Abstract][Full Text] [Related]
17. PAX3 across the spectrum: from melanoblast to melanoma.
Medic S; Ziman M
Crit Rev Biochem Mol Biol; 2009 Jun; 44(2-3):85-97. PubMed ID: 19401874
[TBL] [Abstract][Full Text] [Related]
18. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
19. Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling.
Meurer SK; Tihaa L; Borkham-Kamphorst E; Weiskirchen R
Cell Signal; 2011 Apr; 23(4):683-99. PubMed ID: 21146604
[TBL] [Abstract][Full Text] [Related]
20. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
